[go: up one dir, main page]

DE60119696D1 - Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch - Google Patents

Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Info

Publication number
DE60119696D1
DE60119696D1 DE60119696T DE60119696T DE60119696D1 DE 60119696 D1 DE60119696 D1 DE 60119696D1 DE 60119696 T DE60119696 T DE 60119696T DE 60119696 T DE60119696 T DE 60119696T DE 60119696 D1 DE60119696 D1 DE 60119696D1
Authority
DE
Germany
Prior art keywords
treatment
naltrexone
naloxone
analogs
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60119696T
Other languages
English (en)
Other versions
DE60119696T2 (de
Inventor
Wolfgang Sadee
Danxin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22697044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60119696(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE60119696D1 publication Critical patent/DE60119696D1/de
Application granted granted Critical
Publication of DE60119696T2 publication Critical patent/DE60119696T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60119696T 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch Expired - Lifetime DE60119696T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18937200P 2000-03-15 2000-03-15
US189372P 2000-03-15
PCT/US2001/008225 WO2001068080A2 (en) 2000-03-15 2001-03-15 Neutral antagonists and use thereof in treating drug abuse

Publications (2)

Publication Number Publication Date
DE60119696D1 true DE60119696D1 (de) 2006-06-22
DE60119696T2 DE60119696T2 (de) 2007-01-25

Family

ID=22697044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119696T Expired - Lifetime DE60119696T2 (de) 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Country Status (7)

Country Link
US (2) US20010049375A1 (de)
EP (1) EP1263438B1 (de)
AT (1) ATE326222T1 (de)
AU (1) AU4743601A (de)
CA (1) CA2403252A1 (de)
DE (1) DE60119696T2 (de)
WO (1) WO2001068080A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
ES2540103T3 (es) 2000-02-08 2015-07-08 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
EP1436012B1 (de) * 2001-10-18 2017-12-20 Nektar Therapeutics Polymerkonjugate von opioid antagonisten
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
KR100784341B1 (ko) 2002-04-05 2007-12-13 유로-셀띠끄 소시에떼 아노님 활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP2301537A1 (de) * 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2422772A3 (de) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
DK2316456T3 (en) * 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
RS53279B (sr) * 2003-12-16 2014-08-29 Nektar Therapeutics Monodisperzne smeše pegilisanog naloksola
EP1734955A2 (de) * 2004-01-13 2006-12-27 Duke University Zusammensetzungen eines antikonvulsiven mittels und eines antipsychotischen mittels zur beeinflussung des gewichtsverlustes
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
CN1813740B (zh) * 2005-11-22 2010-05-05 岳振江 一种含有盐酸纳洛酮的舌下膜剂及其制备方法
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2600141T3 (es) 2006-06-19 2017-02-07 Alpharma Pharmaceuticals Llc Composiciones farmacéuticas
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
AU2007319471B9 (en) 2006-11-09 2012-10-04 Nalpropion Pharmaceuticals Llc Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008136989A2 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Polymorphisms in genes affecting sod2-related disorders and uses thereof
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110195433A1 (en) * 2007-12-17 2011-08-11 The Ohio State University Research Foundation Methods for Screening of Opioid Receptor Neutral Antagonists and Inverse Agonists and Uses Thereof
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
SMT201900023T1 (it) 2009-03-10 2019-02-28 Euro Celtique Sa Composizioni farmaceutiche a rilascio immediato comprendenti ossicodone e naloxone
ES2762113T3 (es) * 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
WO2011139525A1 (en) * 2010-05-05 2011-11-10 Philadelphia Health & Education Corporation Stereoisomer of naloxone and potential therapeutic action of opioid drugs to reverse clinical tolerance to these agents
WO2012054566A2 (en) 2010-10-19 2012-04-26 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
KR20210012056A (ko) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
ES2881626T3 (es) 2014-05-30 2021-11-30 Univ New York State Res Found Composiciones y procedimientos para favorecer la formación ósea
EP3291676B1 (de) 2015-04-30 2022-08-17 Memorial Sloan Kettering Cancer Center Mitragynin-analoga und verwendungen davon
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CN108778423A (zh) * 2016-01-08 2018-11-09 俄亥俄州国家创新基金会 阿片类新生儿脱瘾综合征的治疗和预防
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP3600433B1 (de) 2017-03-28 2021-05-05 LDN Pharma Limited Mittel zur erhöhung der expression des bcl2-assoziierten agonisten des zelltods zur behandlung von krebs
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020142644A1 (en) 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
WO2020178447A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method for determining efficacy
WO2021011529A1 (en) 2019-07-15 2021-01-21 Rovaxa Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer
EP4181981A4 (de) 2020-07-17 2024-08-21 Zetagen Therapeutics, Inc. Verfahren und zusammensetzungen zur knochentransplantation mit eisenträgern
US20240325379A1 (en) * 2021-07-06 2024-10-03 Aether Therapeutics Inc. Low-dose naltrexol and uses thereof
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
US12403118B1 (en) 2025-03-05 2025-09-02 Zetagen Therapeutics, Inc. Cancer treatments using modified fatty acids and the carriers to administer them

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
NL280825A (de) 1962-07-11
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5051426A (en) 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
CH683005A5 (it) * 1991-10-30 1993-12-31 Aldo Massarotti Procedimento per la preparazione, mediante ossidazione di N-ossidi per le terapie dei tossicomani da oppiati.
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
WO1996014071A1 (es) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combinacion de farmacos como medicamento destinado a supresion de dependencia de individuos a opiaceos
DE69637089T2 (de) 1995-03-31 2008-01-17 Xenova Research Ltd., Slough Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
EP0828489A4 (de) * 1996-03-13 2001-04-04 Univ Yale Raucherentwöhnungsbehandlung unter verwendung von naltrexon und verwandten verbindungen
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5760044A (en) * 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
EP1011671A1 (de) * 1997-05-20 2000-06-28 Yale University Entwöhnungstherapie mit opiat- und serotoninantagonisten
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion

Also Published As

Publication number Publication date
US6713488B2 (en) 2004-03-30
EP1263438B1 (de) 2006-05-17
AU4743601A (en) 2001-09-24
US20030069262A1 (en) 2003-04-10
WO2001068080A3 (en) 2002-07-04
CA2403252A1 (en) 2001-09-20
DE60119696T2 (de) 2007-01-25
US20010049375A1 (en) 2001-12-06
EP1263438A2 (de) 2002-12-11
WO2001068080A2 (en) 2001-09-20
ATE326222T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
ATE326222T1 (de) Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2302754A1 (en) Noribogaine in the treatment of pain and drug addiction
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
NO20001175D0 (no) Smertestillende blandinger omfattende anti-epileptiske forbindelser og fremgangsmÕter for anvendelse derav
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
KR970009799A (ko) 물질 남용 금단의 치료 방법
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
Moriel et al. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction
ES2253662T3 (es) Procedimiento de tratamiento de un paciente que requiere analgesia.
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
SE9902597D0 (sv) New use
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
Komoda et al. Enhancement of lidocaine-induced epidural anesthesia by deoxyaconitine in the rabbit
WO2007059445A3 (en) Synergistic combinations of norketamine and opioid analgesics
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
US20040198723A1 (en) Method of treatment
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
Hanks Current Availability and Use of Morphine in Developed Countries and Relevance of Alternative Opioids to Morphine in Clinical Practice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition